Hexagon Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Hexagon Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100	Closed	-$8.3K	–	1516
2022 Q4	$8.3K	Sell	100 -9	-8%	-$729	﹤0.01%	772
2022 Q3	$9K	Buy	109 +100	+1,111%	+$8.43K	﹤0.01%	815
2022 Q2	$1K	Buy	9 +2	+29%	+$150	﹤0.01%	1148
2022 Q1	$1K	Buy	7 +6	+600%	+$554	﹤0.01%	902
2021 Q4	$0	Hold	1	–	–	﹤0.01%	907
2021 Q3	$0	Hold	1	–	–	﹤0.01%	895
2021 Q2	$0	Buy	+1	New	+$131	﹤0.01%	855

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Hexagon Capital Partners's XBI Position: Q1 2023 in Review

Hexagon Capital Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 100 shares — an estimated $8.3K sold.

Hexagon Capital Partners first reported a position in XBI in Q2 2021 and held it in 7 quarters. The position peaked at $9K in Q3 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Hexagon Capital Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
Hexagon Capital Partners sold 100 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $8.3K.
Hexagon Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 7 quarters.
Hexagon Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $9K in Q3 2022.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Hexagon Capital Partners's 13F filing for Q1 2023, filed 24 Apr 2023.